Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer.

BACKGROUND/AIMS Survivin, a potential predictive marker to chemotherapeutic drugs, reduces the susceptibility of tumor cells to proapoptotic stimuli, thereby promoting tumor cell survival during tumor treatment with anticancer agents. In the present study, we examined the correlation between drug-response and expression of survivin in gastric cancer. METHODOLOGY Drug-response was performed by histoculture drug-response assay (HDRA) in 42 patients with advanced gastric cancer. Survivin variants was studied by real-time RT-PCR at mRNA levels. RESULTS In our data, twenty-one cases (50%) were sensitive to at least one of drugs tested in the HDRA and 80% (16/20) were positively confirmed clinically, with 100% sensitivity and 83.3% specificity. The diagnostic efficacy of the HDRA were calculated as the area under the receiver operating characteristic (AUC-ROC) curve and showed a value of 0.917. More importantly, significant statistical differences (p=0.012) in chemoresponse to docetaxel were revealed depending on the mRNA level of wild-type survivin. CONCLUSIONS These clinical data demonstrated, for the first time, that wild-type survivin is useful for evaluating the docetaxel-response in patients with gastric cancer. Moreover, the HDRA is an excellent clinical useful drug-response assay for patients to individualize their chemotherapy.

[1]  Mutsushi Yamasaki,et al.  Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. , 2005, Oncology reports.

[2]  N. Tanigawa,et al.  Prognostic significance and different properties of survivin splicing variants in gastric cancer. , 2004, Cancer letters.

[3]  M. Cammer,et al.  Gene expression and mitotic exit induced by microtubule-stabilizing drugs. , 2003, Cancer research.

[4]  Y. Kajimoto,et al.  Transcriptional expression of survivin and its splice variants in brain tumors in humans. , 2003, Journal of neurosurgery.

[5]  N. Tanigawa,et al.  Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. , 2003, Oral oncology.

[6]  G. Colucci,et al.  Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). , 2003, Anticancer research.

[7]  R. Agami,et al.  Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension , 2003, The EMBO journal.

[8]  C. Rödel,et al.  Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. , 2003, International journal of radiation oncology, biology, physics.

[9]  M. Daidone,et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[10]  P. Malfertheiner,et al.  Increased expression of survivin in gastric cancer patients and in first degree relatives , 2002, British Journal of Cancer.

[11]  Alessandra Giodini,et al.  Regulation of microtubule stability and mitotic progression by survivin. , 2002, Cancer research.

[12]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[13]  M. Daidone,et al.  Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Kaibara,et al.  Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment , 2002, Apoptosis.

[16]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.

[17]  D. Altieri,et al.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. , 1999, Cancer research.

[18]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[19]  Y. Maehara,et al.  Treatment of advanced gastric cancer with 5-fluorouracil and cisplatin in combination with dipyridamole. , 1998, International journal of oncology.

[20]  M Dietel,et al.  Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. , 1998, Journal of biochemical and biophysical methods.

[21]  M. Tattersall,et al.  Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. , 1996, British Journal of Cancer.

[22]  R. Hoffman,et al.  Clinical applications of the histoculture drug response assay. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Masahiko Watanabe,et al.  High in vitro‐in vivo correlation of drug response using sponge‐gel‐supported three‐dimensional histoculture and the MTT end point , 1992, International journal of cancer.

[24]  M. Bissery,et al.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. , 1991, Cancer research.

[25]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[26]  P. Schein,et al.  Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study. , 1986, Cancer treatment reports.

[27]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[28]  S. Carter,et al.  Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. , 1974, Cancer treatment reviews.

[29]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[30]  D. Altieri.  Survivin and apoptosis control. , 2003, Advances in cancer research.

[31]  A. Nakao,et al.  Evaluation of the Histoculture Drug Response Assay as a Sensitivity Test for Anticancer Agents , 2002, Surgery Today.